Spago Nanomedical AB (publ) (STO:SPAGO)

Market Cap	77.73M +1.5%
Revenue (ttm)	4.82M -27.5%
Net Income	-26.55M
EPS	-0.07
Shares Out	661.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,960
Average Volume	211,492
Open	0.1075
Previous Close	0.1175
Day's Range	0.1075 - 0.1335
52-Week Range	0.0842 - 0.4600
Beta	1.36
RSI	53.87
Earnings Date	May 6, 2026

About Spago Nanomedical AB

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage. The company wa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 7
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SPAGO

Financial Performance

In 2025, Spago Nanomedical AB's revenue was 4.82 million, a decrease of -27.53% compared to the previous year's 6.65 million. Losses were -26.55 million, -18.32% less than in 2024.